Agenus Inc Reports Q2 2025 Earnings: EPS Loss of $2.03, Revenue at $25.7 Million, Missing Estimates.

Agenus Inc reported Q2 2025 earnings with a revenue of $25.7 million, missing estimates. The company's net loss improved to $56.4 million, or $2.03 per share, compared to a net loss of $118.3 million, or $5.56 per share, in Q2 2024. Agenus is expected to receive a $91 million capital infusion from a strategic collaboration with Zydus Lifesciences, supporting its clinical and regulatory objectives.

Agenus Inc (AGEN), a clinical-stage biotechnology company focused on developing therapies to activate the immune system against cancer and infections, reported its second-quarter (Q2) 2025 earnings on August 11, 2025. The company's financial performance was marked by a significant reduction in net loss, despite missing revenue estimates.

Agenus reported a revenue of $25.7 million for Q2 2025, falling short of the estimated $49.71 million. The company's revenue primarily stems from non-cash royalty revenue [1]. Despite the revenue shortfall, Agenus's net loss for Q2 YTD 2025 improved to $56.4 million, or $2.03 per share, compared to a net loss of $118.3 million, or $5.56 per share, in Q2 YTD 2024. This improvement is attributed to effective cost management, with cash used in operations decreasing to $45.8 million for Q2 YTD 2025 from $76.4 million in Q2 YTD 2024 [1].

A key strategic partnership is expected to bolster Agenus's financial stability and clinical progress. The company anticipates a $91 million capital infusion from Zydus Lifesciences, with the collaboration set to close in Q3 2025. This infusion will support the company's clinical and regulatory milestones, including the launch of its Phase 3 trial [1].

Agenus's BOT/BAL combination therapy has shown promising results, delivering a 42% two-year survival rate in refractory MSS colorectal cancer (CRC) and consistent activity across multiple solid cancers. The company's regulatory alignment for a streamlined Phase 3 trial design is expected to commence in Q4 2025 [2].

Looking ahead, Agenus is committed to advancing its clinical programs and securing additional funding streams. The company expects its liquidity to improve with the anticipated $91 million infusion from the Zydus collaboration, positioning it to achieve its long-term objectives in the biotechnology industry [1].

References:
[1] https://www.gurufocus.com/news/3057853/agenus-inc-reports-q2-2025-earnings-eps-loss-of-203-revenue-at-257-million-missing-estimates
[2] https://finance.yahoo.com/news/agenus-announces-second-quarter-2025-113000375.html